造血评分系统对初诊多发性骨髓瘤患者的预后价值

刘宁洒; 李玉陶; 徐晓奇; 石巧梅; 李护君; 王莹; 李德鹏; 徐开林; 李振宇

doi:10.13201/j.issn.1004-2806.2021.01.004

造血评分系统对初诊多发性骨髓瘤患者的预后价值

- 徐州医科大学附属医院血液科(江苏徐州, 221002)
基金项目:
江苏省医学重点人才项目(No:ZDRCA2016052)

详细信息

通讯作者: 李振宇,E-mail:lizhenyumd@163.com

中图分类号: R733.3

收稿日期: 2020-10-14

Analysis of prognostic value of hematopoietic indices in patients with multiple myeloma

- Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China

More Information

Corresponding author: LI Zhenyu, E-mail: lizhenyumd@163.com

Received Date: 14 October 2020

摘要

摘要: 目的:回顾性分析平均红细胞体积、血红蛋白及血小板计数组成的造血评分(HS)系统对初诊多发性骨髓瘤(MM)患者的预后价值。方法:收集整理2012年2月至2019年1月我院血液科收治的179例新诊断MM患者的临床资料及生存情况。根据HS系统将所有患者分为0,1,2,3分共4组,通过受试者工作特性曲线分析得出最佳截断值,将HS系统分为高分组(2~3分)和低分组(0~1分)。利用χ²检验比较组间差异,生存率的计算和比较采用Kaplan-Meier法和Log-rank检验,使用Cox回归进行单因素、多因素预后相关性分析。结果:高分组与低分组在年龄、β2-微球蛋白、乳酸脱氢酶、ISS分期、DS分期方面差异有统计学意义(P＜0.05)。单因素分析结果显示,年龄、血红蛋白、血小板计数、乳酸脱氢酶、ISS分期、DS分期、β2-微球蛋白、HS、白蛋白、骨髓浆细胞比例是MM的不良预后因素(P＜0.05)。多因素Cox分析模型表明,HS、年龄、白蛋白、乳酸脱氢酶、骨髓浆细胞是影响MM患者总生存的独立危险因素(P＜0.05)。结论:初诊时HS越高提示预后不良,是MM的独立危险因素。
- 多发性骨髓瘤 /
- 造血评分 /
- 预后
Abstract: Objective: To retrospectively analyze the prognostic value of the hematopoietic score(HS) system composing mean red blood cell volume, hemoglobin and platelet count for newly diagnosed multiple myeloma(MM) patients.Methods: The clinical data and survival status of 179 newly diagnosed MM patients admitted to our hospital from February 2012 to January 2019 were collected. According to the HS system, patients were divided into four groups of 0, 1, 2, and 3 points. The best cut-off value was obtained through receiver operating characteristic curve analysis, and based on the HS system, it was divided into higher points group(2-3 points) and lower points group(0-1 points). We used the χ²test to compare the differences between groups, the Kaplan-Meier method and Log-rank test to calculate and compare the survival rate, and the Cox regression to analyze the univariate and multivariate prognostic correlation.Results: There were statistically significant differences between the higher and lower points groups in age, β2-microglobulin, lactate dehydrogenase, ISS staging, and DS staging(P＜0.05). The results of univariate analysis showed that age, hemoglobin, platelet count, lactate dehydrogenase, ISS staging, DS staging, β2-microglobulin, HS, albumin, bone marrow plasma cell ratio were related to poor prognostic factors of MM(P＜0.05). Multivariate Cox analysis model showed that HS, age, albumin, lactate dehydrogenase, bone marrow plasma cells were independent risk factors that affect overall survival of MM patients(P＜0.05).Conclusion: The higher the HS at the first diagnosis, the poor prognosis, which is an independent risk factor of MM.
- multiple myeloma /
- hematopoietic score /
- prognostic

HTML全文

参考文献(19)

[1]	Rajkumar SV.Multiple myeloma:Every year a new standard[J].Hematol Oncol,2019,37(Suppl 1):62-65.
[2]	Castaneda O,Baz R.Multiple Myeloma Genomics-A Concise Review[J].Acta Med Acad,2019,48(1):57-67.
[3]	Hari PN,Zhang MJ,Roy V,et al.Is the International Staging System superior to the Durie-Salmon staging system?A comparison in multiple myeloma patients undergoing autologous transplant[J].Leukemia,2009,23(8):1528-1534.
[4]	Bustoros M,Mouhieddine TH,Detappe A,et al.Established and Novel Prognostic Biomarkers in Multiple Myeloma[J].Am Soc Clin Oncol Educ Book,2017,37:548-560.
[5]	Mikhael JR,Dingli D,Roy V,et al.Management of newly diagnosed symptomatic multiple myeloma:updated Mayo Stratification of Myeloma and Risk-Adapted Therapy(mSMART)consensus guidelines 2013[J].Mayo Clin Proc,2013,88(4):360-76.
[6]	Al Saleh AS,Sidiqi MH,Dispenzieri A,et al.Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients[J].Am J Hematol,2020,95(1):4-9.
[7]	[2014 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma][J].Nihon Rinsho,2016,74(Suppl 5):264-268.
[8]	Kumar S,Paiva B,Anderson KC,et al.International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J].Lancet Oncol,2016,17(8):e328-e346.
[9]	Kumar SK,Callander NS,Alsina M,et al.NCCN Guidelines Insights:Multiple Myeloma,Version 3.2018[J].J Natl Compr Canc Netw,2018,16(1):11-20.
[10]	Joshua DE,Bryant C,Dix C,et al.Biology and therapy of multiple myeloma[J].Med J Aust,2019,210(8):375-380.
[11]	李昕,侯健.单克隆抗体治疗多发性骨髓瘤新进展[J].临床血液学杂志,2020,33(7):451-455.
[12]	周慧星,陈文明.初诊多发性骨髓瘤患者的治疗进展——2018 ASH报道[J].临床血液学杂志,2019,32(1):64-67.
[13]	Cucuianu A,Patiu M,Rusu A.Hepcidin and multiple myeloma related anemia[J].Med Hypotheses,2006,66(2):352-354.
[14]	Mittelman M.The implications of anemia in multiple myeloma[J].Clin Lymphoma,2003,4(Suppl 1):S23-S29.
[15]	任明强,陈琦.多发性骨髓瘤血清TPO水平动态监测及临床意义[J].遵义医学院学报,2006,29(2):122-123.
[16]	Kyle RA,Gertz MA,Witzig TE,et al.Review of 1027 patients with newly diagnosed multiple myeloma[J].Mayo Clin Proc,2003,78(1):21-33.
[17]	Jomrich G,Hollenstein M,John M,et al.High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma[J].Ann Surg Oncol,2019,26(4):976-985.
[18]	Nagai H,Yuasa N,Takeuchi E,et al.The mean corpuscular volume as a prognostic factor for colorectal cancer[J].Surg Today,2018,48(2):186-194.
[19]	Hata H,Matsuzaki H,Yoshida M,et al.Red blood cell volume(MCV)as a new prognostic factor of multiple myeloma[J].Eur J Haematol,1995,54(1):57-58.